Meta-analysis showing the beneficial effect of α-blockers on ureteric stent discomfort

BJU International

Volumn 108, Issue 11, 2011, Pages 1894-1902

  Lamb, Alastair D ^a   Vowler, Sarah L ^b   Johnston, Richard ^a   Dunn, Nick ^c   Wiseman, Oliver J ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

adrenergic antagonists; meta analysis; stents; symptoms; ureter

Indexed keywords

ALFUZOSIN; BUPRENORPHINE; CODYDRAMOL; PLACEBO; PRULIFLOXACIN; QUINOLONE; TAMSULOSIN;

APPLICATION SITE DISCOMFORT; ARTICLE; CLINICAL ASSESSMENT TOOL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; FOLLOW UP; HEALTH CARE QUALITY; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; NAUSEA AND VOMITING; ORTHOSTATIC HYPOTENSION; PAIN ASSESSMENT; PATIENT COMPLIANCE; POSTOPERATIVE PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SCORING SYSTEM; SYSTEMATIC REVIEW; TREATMENT DURATION; URETER STENT; URETERAL STENT SYMPTOM QUESTIONNAIRE; URETERIC STENT DISCOMFORT; XEROSTOMIA;

ADRENERGIC ALPHA-ANTAGONISTS; HUMANS; PAIN MEASUREMENT; PAIN, POSTOPERATIVE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STENTS; TREATMENT OUTCOME; URETERAL OBSTRUCTION; URINATION DISORDERS;

EID: 81255134317     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10170.x     Document Type: Article

References (38)

1. Nabi G, Cook J, N'Dow J, McClinton S,. Outcomes of stenting after uncomplicated ureteroscopy: systematic review and meta-analysis. BMJ 2007; 334: 572
2. Joshi HB, Newns N, Stainthorpe A, MacDonagh RP, Keeley FX Jr, Timoney AG,. Ureteral stent symptom questionnaire: development and validation of a multidimensional quality of life measure. J Urol 2003; 169: 1060-4 (Pubitemid 36188159)
3. Hollingsworth JM, Rogers MA, Kaufman SR, et al,. Medical therapy to facilitate urinary stone passage: a meta-analysis. Lancet 2006; 368: 1171-9 (Pubitemid 44441578)
4. Parsons JK, Hergan LA, Sakamoto K, Lakin C,. Efficacy of alpha-blockers for the treatment of ureteral stones. J Urol 2007; 177: 983-7 (Pubitemid 46216377)
5. Schuler TD, Shahani R, Honey RJ, Pace KT,. Medical expulsive therapy as an adjunct to improve shockwave lithotripsy outcomes: a systematic review and meta-analysis. J Endourol 2009; 23: 387-93
6. Singh A, Alter HJ, Littlepage A,. A systematic review of medical therapy to facilitate passage of ureteral calculi. Ann Emerg Med 2007; 50: 552-63 (Pubitemid 47600389)
7. Seitz C, Liatsikos E, Porpiglia F, Tiselius HG, Zwergel U,. Medical therapy to facilitate the passage of stones: what is the evidence? Eur Urol 2009; 56: 455-71
8. Zhu Y, Duijvesz D, Rovers MM, Lock TM,. alpha-blockers to assist stone clearance after extracorporeal shock wave lithotripsy: a meta-analysis. BJU Int 2010; 106: 256-61
9. Lam T, MacLennan G, Thomas R, N'Dow J, MacLinton S,. The Use of Medical Expulsive Therapy: The Evidence Base. Aberdeen: BAUS Section of Endourology, 2010
10. Kubacz GJ, Catchpole BN,. The role of adrenergic blockade in the treatment of ureteral colic. J Urol 1972; 107: 949-51
11. Davenport K, Timoney AG, Keeley FX,. A comparative in vitro study to determine the beneficial effect of calcium-channel and alpha(1)-adrenoceptor antagonism on human ureteric activity. BJU Int 2006; 98: 651-5 (Pubitemid 44185893)
12. Rajpathy J, Aswathaman K, Sinha M, Subramani S, Gopalakrishnan G, Kekre NS,. An in vitro study on human ureteric smooth muscle with the alpha1-adrenoceptor subtype blocker, tamsulosin. BJU Int 2008; 102: 1743-5
13. Nakada SY,. Tamsulosin: ureteric motility. BJU Int 2008; 101: 1061-2 (Pubitemid 351502666)
14. Thomas R,. Indwelling ureteral stents: impact of material and shape on patient comfort. J Endourol 1993; 7: 137-40 (Pubitemid 23159581)
15. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF,. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999; 354: 1896-900
16. Moher D, Schulz KF, Altman DG,. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001; 357: 1191-4 (Pubitemid 32378696)
17. Jadad AR, Moore RA, Carroll D, et al,. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12 (Pubitemid 26120810)
18. Schulz KF, Chalmers I, Hayes RJ, Altman DG,. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 408-12
19. Imamura M, Cook J, Maclennan S, N'Dow J, Dahm P,. Evidence-based urology in practice: heterogeneity in a systematic review meta-analysis. BJU Int 2010; 105: 770-3
20. Higgins JP, Thompson SG, Deeks JJ, Altman DG,. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60 (Pubitemid 37088507)
21. Team RDC,. R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing, 2009
22. Lumley T,. rmeta: Meta-analysis. 2009; R package, version 2.16. Available at
23. Armitage P, Berry G,. Statistical Methods in Medical Research, 3rd edn. London: Blackwell, 1994
24. Newcombe RG,. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998; 17: 857-72 (Pubitemid 28185165)
25. Beddingfield R, Pedro RN, Hinck B, Kreidberg C, Feia K, Monga M,. Alfuzosin to relieve ureteral stent discomfort: a prospective, randomized, placebo controlled study. J Urol 2009; 181: 170-6
26. Damiano R, Autorino R, De Sio M, Giacobbe A, Palumbo IM, D'Armiento M,. Effect of tamsulosin in preventing ureteral stent-related morbidity: a prospective study. J Endourol 2008; 22: 651-6
27. Deliveliotis C, Chrisofos M, Gougousis E, Papatsoris A, Dellis A, Varkarakis IM,. Is there a role for alpha1-blockers in treating double-J stent-related symptoms? Urology 2006; 67: 35-9 (Pubitemid 43069251)
28. Park SC, Jung SW, Lee JW, Rim JS,. The effects of tolterodine extended release and alfuzosin for the treatment of double-j stent-related symptoms. J Endourol 2009; 23: 1913-7
29. Wang CJ, Huang SW, Chang CH,. Effects of specific alpha-1A/1D blocker on lower urinary tract symptoms due to double-J stent: a prospectively randomized study. Urol Res 2009; 37: 147-52
30. Wang CJ, Huang SW, Chang CH,. Effects of tamsulosin on lower urinary tract symptoms due to double-J stent: a prospective study. Urol Int 2009; 83: 66-9
31. Cochrane. Cochrane Handbook for Systematic Reviews of Interventions, version 5.0.2. Section 16.1.3.1. The Cochrane Collaboration, 2009. Available at:. Accessed 2 September 2010
32. The EuroQol Group. EuroQol-A New Facility for the Measurement of Health-Related Quality of Life. Amsterdam: Health Policy, 1990: 16: 199-208
33. Dellabella M, Milanese G, Muzzonigro G,. Medical-expulsive therapy for distal ureterolithiasis: randomized prospective study on role of corticosteroids used in combination with tamsulosin-simplified treatment regimen and health-related quality of life. Urology 2005; 66: 712-5 (Pubitemid 41440809)
34. Porpiglia F, Ghignone G, Fiori C, Fontana D, Scarpa RM,. Nifedipine versus tamsulosin for the management of lower ureteral stones. J Urol 2004; 172: 568-71 (Pubitemid 38900206)
35. Micali S, Grande M, Sighinolfi MC, De Stefani S, Bianchi G,. Efficacy of expulsive therapy using nifedipine or tamsulosin, both associated with ketoprofene, after shock wave lithotripsy of ureteral stones. Urol Res 2007; 35: 133-7 (Pubitemid 46828945)
36. Merck. Alfuzosin and Tamsulosin Drug Information. Merck Manuals Online Medical Library 2009. Available at:. Accessed 25 May 2010
37. Lang RJ, Davidson ME, Exintaris B,. Pyeloureteral motility and ureteral peristalsis: essential role of sensory nerves and endogenous prostaglandins. Exp Physiol 2002; 87: 129-46 (Pubitemid 34257028)
38. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR,. Publication bias in clinical research. Lancet 1991; 337: 867-72